Refractory Myasthenia Gravis

Rituximab Shows Promise for Refractory Myasthenia Gravis

Rituximab Shows Promise for Refractory Myasthenia Gravis

Most patients required a least a year to completely withdraw from immunotherapy in order to demonstrate a clinical remission.

Sign Up for Free e-Newsletters